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Bronchial biopsy provides valuable information about the inflammatory processes in lung tissue, but optimal 
results are only achieved if the design of intervention studies is sufficiently rigorous. The parallel-group design has 
merit, but the cross-over design is statistically superior, providing the wash-out period is effective. Heterogeneity of 
contributing pathologies in asthma patients results in large inter-patient variability which must be controlled for, 
for example by using strict inclusion criteria, which should ideally relate to the specific inflammatory marker being 
studied. The inclusion of a placebo group helps to quantify sample variability. 
The study must have sufficient statistical power to detect inter-group differences for each variable; appropriate 
adjustments should be made when multiple tests are used. Studies with larger patient numbers are best performed 
using a multi-centre design, with one centre analysing all tissue samples to reduce variability. Study duration 
depends on the type of investigation, but should ideally be short. Longer studies are necessary to evaluate chronic 
changes such as tissue remodelling. 
Changes in clinical status and cellular events may follow different time courses after intervention. Biopsy 
measurements are less reproducible than physiological tests, and diurnal variation in the number and function of 
inflammatory cells can further complicate measurement. The timing of clinical trial assessments needs to allow for 
these idiosyncrasies. Finally, a balance must be maintained between the risk, albeit small, and the benefit of 
performing bronchial biopsies. 
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Introduction 
When assessing how drugs modify inflammation in the 
lung, the most direct form of measurement is to study 
samples of lung tissue. Studies using animal lung may give 
valuable data, but the findings need to be confirmed in the 
clinical setting. Although bronchial biopsies are particularly 
suitable for pathophysiology studies, they can also be used 
to provide secondary outcome measures in clinical trials, if 
the study objectives are kept simple. 
The methodology of bronchial biopsy, i.e. how the 
sample is taken, preserved, sectioned and analysed, has a 
considerable influence on the results that are obtained and 
guidelines have been published for the benefit of investiga- 
tors working in this field (1). However, the basic design of 
asthma studies that include biopsy assessments (e.g. size, 
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duration and patient selection) may affect the validity and 
value of the outcome even more profoundly. This paper 
reviews the most important elements of biopsy study 
design. 
Study designs 
CROSS-OVER DESIGNS 
The best design for biopsy studies is the cross-over, which is 
preferable to parallel-group, provided that steps are taken 
to resolve the inherent problems of the design. The main 
advantage of cross-over studies is that patients act as their 
own controls, so inter-subject variability is reduced and 
fewer patients are required to achieve a given statistical 
power than in parallel-group studies. Small-scale cross-over 
studies are appropriate for hypothesis generation (explora- 
tory studies) and can be run in a single centre; this design is 
also particularly suitable for allergen challenge studies (2,3). 
A cross-over design requires more biopsies to be taken 
from each subject, however, this, coupled with the longer 
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FIG. 1. Ideal cross-over design for use in a two-arm 
bronchial biopsy study. B = time points when biopsies are 
taken. 
duration of the study, may discourage patient entry. For 
studies with three or more treatment arms, this problem can 
be directly addressed by the use of an ‘incomplete block’ 
design. 
Statistical analysis of data in cross-over studies is 
straightforward, although it is frequently difficult to assess 
how long the wash-out period should be to ensure that no 
drug effects carry over into the subsequent treatment 
period. In a long-term study, six of 18 patients with mild 
asthma who received placebo for 1 year after 2 year’s 
treatment with budesonide 1200 ugday- ’ maintained the 
lung function improvements achieved in the first 2 years, 
and only three of the 18 patients had to withdraw from the 
study during the third year because of inadequate treatment 
(4); this shows that participation in the trial produced 
clinical benefits, but also suggests that the effects of 
treatment with inhaled corticosteroids (ICS) may persist 
after treatment discontinuation. 
In the ideal cross-over design, which should be double- 
blind, four bronchoscopy procedures with biopsy sampling 
should be performed, before and after each treatment 
period (Fig. 1). The pretreatment sample allows intra- 
subject variability to be better controlled for. If the 
treatment and wash-out periods are short, four samples 
may not be practicable, as patients cannot tolerate frequent 
bronchoscopies; however, omitting the pretreatment sample 
need not be a problem if placebo is included as one of the 
treatments. Some variability between subjects may still 
remain in cross-over studies, resulting from the differences 
in underlying pathology between study participants. 
Analysis of the study results requires treatment effects to 
be averaged across subjects; therefore, the patient sample 
needs to be made as homogeneous as possible. This can be 
achieved by using strict inclusion criteria to select specific 
patient subsets. 
PARALLEL GROUP 
Strict inclusion criteria can also be employed to reduce 
variability in parallel-group studies; another common 
approach is to recruit large numbers of patients. In a 
heterogeneous patient population such as asthmatics, the 
recruitment of larger treatment groups allows for 
the increased variability, and increases the probability 
of the groups being well balanced. In large studies, it may 
also be possible to create better-balanced groups by 
stratifying patients into sub-groups; differences in the 
pathophysiology can be expected according to a patient’s 
atopic or smoking status, the co-existence of COPD, and 
disease severity (558). 
For a given treatment protocol, the treatment period in a 
parallel-group study is shorter than in a cross-over 
study. When the treatment period is longer than 6 months, 
patient withdrawals may become a serious problem, and 
parallel-group studies may therefore be the more feasible 
option. However, performing biopsies on large numbers of 
patients may increase the complexity and cost of the study. 
If the levels of the chosen inflammatory marker vary with 
time in the normal disease state, inclusion of a placebo 
group is essential (irrespective of study design). A placebo 
group can also help to quantify the population variability in 
studies where this is expected to be large. A beneficial 
placebo effect is often observed (9), which must be 
accounted for when interpreting treatment effects. It may 
be unethical, however, to ‘withhold active treatment in 
long-term studies unless patients have very mild disease. 
Controlling variability 
PATIENT NUMBERS AND STATISTICAL 
CONSIDERATIONS 
The statistical plan of a clinical study which includes 
bronchial biopsies must address two common problems- 
multiple comparisons and large inter-patient variability. It 
is quite common for 10 or more markers to be measured in 
biopsy studies, but as the number of tests increases, so does 
the chance of finding a significant difference where one does 
not exist (Type I error) (10). For example, if eight tests are 
performed, the probability of making a Type I error (M) 
may be as great as one in three, depending on the degree of 
correlation between measures, and so adjustment methods 
must be used (11). The use of a Bonferroni correction to 
reduce a is not appropriate when the measurements being 
made are highly correlated (12). For a given inter-treatment 
difference, the only way to increase the power of the study 
without affecting the probability of a Type I error is to 
increase the sample size. The study protocol should include 
a calculation of sample size and study power (on the basis 
of the primary efficacy parameter), and if scrutiny of the 
study data shows that these are not achieved, the differences 
should be noted in the study report. 
An additional source of variability in bronchial biopsy 
studies is the change in the disease process over time. 
In one group of 12 patients with stable asthma, the intra- 
subject differences in inflammatory cell counts (T-cell and 
eosinophil markers) between two biopsies taken 1 month 
apart was much greater than the intra-subject difference 
between upper and lower lobe samples, despite no change 
being observed in treatment, forced expiratory volume in 1 
second (FEVr), symptoms or bronchial hyper-reactivity 
(13). By analysing the observed variation in cell counts in 
this study, the authors concluded that 15 patients would be 
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FIG. 2. Relationship between the number of patients 
enrolled in a biopsy study and the detectable difference 
between pre- and post-treatment biopsy cell counts (for 
three lymphocyte markers and an eosinophil marker), 
assuming a power of 80% to detect a difference significant 
at the P<O.O5 level. [Reproduced from Richmond et al. 
(1996) with permission (13)]. 
needed per treatment group in a parallel-group biopsy 
study to obtain 80% statistical power to detect a significant 
difference in inflammatory cell counts, and eight per group 
in a cross-over design (13); however, the differences 
detected would need to be large (Fig. 2). 
The large variability is often evident in the form of large 
differences in baseline values of inflammatory cell count or 
concentration of markers; these may be greater than the 
difference that results from the study treatment (14). On 
such occasions, the most useful measure for comparison 
may be change from baseline (effectively normalising the 
baseline readings), but caution is still needed with 
interpretation. The variation in baseline readings may 
indicate that patients have different underlying pathologies. 
VARIATION IN CONTRIBUTING 
PATHOLOGY 
Although different asthmatic patients may have similar 
clinical signs and symptoms, the immunological, biochem- 
ical and structural abnormalities that contribute to the 
pathology of each patient may differ. Various alterations in 
the structure or function of cells or tissues may be present at 
any one time, yet the sum of all the abnormalities gives rise 
to similarity in the clinical expression of asthma. A patient 
only presents with asthma if the aggregate effect of these 
alterations is large enough to reach the threshold for 
clinical symptoms. This is illustrated in Fig. 3, where each 
contributing factor is represented by a letter. In patient 1, a 
combination of abnormalities in factors A and B is 
present, but does not reach a level sufficient to cause a 
clinically detectable change; however, patient 2, whose 
major abnormality is factor A, presents with asthma 
because the aggregate of the abnormal factors exceeds the 
- 
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FIG. 3. Contribution of different pathological 
abnormalities (A to F) to total symptomatology in four 
hypothetical asthma patients. Dotted line = threshold 
above which patient presents with typical asthma 
symptoms. 
threshold. Although the clinical presentation of patient 3 is 
identical to patient 2, the major underlying abnormality is B. 
Patient 4, despite no abnormality in A or B, also presents 
with asthma because of abnormalities in factors C, D, E 
and F. Despite their contrasting underlying pathological 
profiles, patients 2, 3 and 4 cannot be distinguished from 
each other simply on the basis of clinical measurements, 
e.g. FEVi, airway hyper-reactivity or symptom measures. 
When patients are recruited for clinical trials in which 
only clinical outcomes are measured, the use of clinical tests 
as inclusion criteria is appropriate. However, when a trial is 
designed to assess the capacity of a drug to correct one 
abnormal factor, recruitment according to results of clinical 
tests is inadequate, and is certain to increase the variability 
of responses to the agent under study. For example, a drug 
which was designed to reduce numbers or function of T- 
cells would be more likely to be effective in a patient with 
an abnormality in T-cell reactivity than a patient with 
normal cell reactivity. By adding an assessment of the 
specific mechanistic marker to the inclusion criteria, either 
directly or via a surrogate, those patients who are more 
likely to respond (at both the cellular and clinical level) can 
be distinguished, making the trial more productive. In order 
to achieve greater homogeneity of patient phenotype in 
clinical trials, validated surrogate markers in sputum, 
blood, urine or exhaled air are required for a variety of 
inflammatory cells and processes. These markers will 
allow appropriate subjects to be selected for specific 
investigations, and make research outcomes more reliable 
and reproducible. 
PATIENT SELECTION 
Inter-patient variability may also be reduced by stratifying 
patient groups in biopsy studies as described previously. An 
alternative approach to stratification is to perform a ‘run- 
in’ biopsy; only those patients whose levels of a target 
inflammatory marker exceed a set threshold are rando- 
mized to treatment. However, performing a separate biopsy 
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analysis in this way runs counter to best biopsy practice, i.e. 
preparing, sectioning and staining all biopsies from one 
study in a single operation. This approach will also increase 
regression to the mean, since some of the patients who meet 
the test criterion may have unusually high levels of the 
target marker compared to their normal range, and these 
are likely to fall subsequently. This will not cause a 
treatment group imbalance if patients are randomized after 
the result of the run-in test is known. 
As previously stated, it is easier to assess the scale of 
inter-patient variability when large numbers of patients are 
enrolled; subgroup analysis is also more practicable. The 
fastest way to recruit large patient numbers is to perform a 
multicentre study. Although there may be an increase in 
variability because of inter-centre differences in biopsy 
preparation and bronchoscopy method, the variability of 
methodology is small in comparison with that between 
patients. Indeed, inter-centre variability can be obviated by 
nominating one centre to process and analyse all biopsies, 
enabling the methodology to be better standardized. It is 
vital that study centre staff are properly trained to take and 
prepare biopsies, and that there is sufficient time and 
funding to produce high-quality results. 
Large-scale clinical trials that include biopsy assessment 
are costly, but their value can be increased by ‘banking’ the 
biopsy samples after completion of the study. Samples 
taken from healthy volunteers or from asthma patients 
treated with placebo may be a source of historical control 
data for future work. In addition, banked samples can be 
re-analysed at a later date, either to assay markers that are 
subsequently characterized or discovered, or to make use of 
improved assay methods that may become available in the 
future. 
Study duration 
Deterioration in compliance with treatment and the loss 
of patients to follow-up impose a practical limitation on the 
duration of asthma studies; however, valuable information 
on the natural history of asthma may be obtained by 
performing repeat biopsies on patients for many. years. 
In order to assess the long-term effects of treatment on 
inflammation and airway remodelling, a study should last 
for a minimum of 1 year, with biopsies taken at baseline, 
3, 6 and 12 months. However, the study design should 
include adequate controls to account for the natural 
variability of the target inflammatory marker over this 
time period. Indeed, reproducibility of inflammatory cell 
counts from biopsies shows a pronounced decline as the 
interval between consecutive biopsies is prolonged (15). 
Studies should not be so short that treatments have 
insufficient time to achieve clinical benefit. For example, 
2-3 months of ICS therapy may be required before effects 
on some lung function and immunological parameters are 
observed (16,17). An observed effect of drug treatment on 
the number of cells in a biopsy sample may be made more 
definitive by measuring whether the cell count returns to 
normal after withdrawal of treatment. The interval between 
stopping treatment and taking the final biopsy should be 
carefully judged, to avoid provoking ethical objections if 
patients have severe disease. 
Integrating biopsy assessments into 
clinical trials 
The time points selected for biopsy assessments during a 
clinical study may introduce additional sources of varia- 
bility. The diurnal variation of lung function measures 
such as peak expiratory flow is well recognized (18) and 
is routinely taken into account in the timing of clinic&l 
assessments. However, the time of day at which broncho- 
scopy is performed also has an inffuence on the test result; 
inflammatory cell counts in the alveoli of patients with 
nocturnal asthma were shown to be significantly higher at 
04.00 hours than at 16.00 hours in biopsies taken 1 week 
apart (19). 
Results from a controlled parallel-group study that 
featured clinical and biopsy assessments suggest that the 
timescale of changes at the clinical and cellular level are 
different. In that study, biopsies were taken at baseline, 2 
and 8 weeks from 27 asthmatic patients treated with either 
fluticasone propionate (FP) 2mgdayy’ or placebo (17). 
Significant improvements from baseline were recorded in 
spirometry variables after 2 weeks in the FP group 
compared with placebo, but there was no further improve- 
ment at 8 weeks. However, reductions in the number of 
inflammatory cells followed different time courses; after 2 
weeks, the number of T-cells and primed T-cells (expressed 
as a ratio to the baseline count) was significantly lower in 
the FP group than the placebo group, but the correspond- 
ing change in activated eosinophil (EG2+) numbers took 8 
weeks to reach significance. 
The exact timing of clinical assessments such as the P&s 
is not critical, since this parameter is highly reproducible 
over time (20). However, a recent study in which nine 
atopic asthma patients who received no drug intervention 
underwent clinical and biopsy assessments at three time 
points (baseline, 2 and 8 weeks) suggests that this may 
not apply to biopsy results. Although baseline physiology 
measurements such as PC& FEVi, mid-range forced 
expiratory flow (FEFZS& and BDR were highly repro- 
ducible at 2 and 8 weeks, the biopsy data were reproducible 
only at 2 weeks; at 8 weeks, the intra-class coefficients of all 
cell counts other than that for EG2+ were below 0.6, 
indicating that repeat measurements of these variables are 
poorly reproducible (15). 
Safety 
Bronchoscopy is a potentially hazardous procedure: the 
most common problem is bronchospasm and associated 
dyspnoea, but there is a small risk of fever, bleeding and, 
with transbronchial biopsy, pneumothorax (21). Exposing 
the patient to these risks must always be justified by the 
potential value of the research results. If the target variable 
can be satisfactorily measured by using another safer 
assessment method, bronchoscopy should not be performed. 
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This risk analysis is particularly important for patients who 
will receive placebo. 
Consideration should also be given to the patient’s 
comfort during and after bronchoscopy. The use of the 
short-acting general anaesthetic propofol to sedate patients 
during bronchoscopy is associated with faster recovery and 
a lower incidence of drowsiness after the procedure than 
sedation with midazolam (C. Burke. personal communica- 
tion), although the product licence for propofol stipulates 
the attendance of an experienced anaesthetist. 
Study centres should have established procedures to 
ensure adherence to appropriate guidelines for asthma 
studies and for bronchoscopy. For example, clinicians who 
perform bronchoscopies for investigating centres should 
participate in an ‘on-call’ system to ensure that expert help 
is permanently available by telephone to patients or 
volunteers enrolled in the study, their family doctors and 
the hospital’s emergency department. If the patients are not 
well acquainted with the medical or paramedical staff, the 
study team should develop a system for follow-up calls to 
the patients at 12 and 24 h after bronchoscopy. 
Conclusions 
Bronchial biopsy studies need to be carefully designed and 
executed at the clinical and physiological level. It is not 
ideal for biopsy assessments to be simply added on to an 
existing clinical trial protocol. 
When planning a study, the main elements of the 
protocol, e.g. design, scale, patient selection, duration and 
assessment methods should be considered with particular 
reference to the special requirements of biopsy. It is 
important that a primary biopsy variable is defined for 
confirmatory studies, as well as the size of effect that is 
sought. Measures should be taken to control variability, 
and when assessment time points are selected, allowance 
must be made for differences in the time course of 
changes at the cellular and physiological levels. By paying 
sufficient attention in advance to these elements of the 
design process, the quality of the study will inevitably be 
improved. 
References 
1. Saetta M, Jeffery PK, Maestrelli P, Timens W. 
Biopsies: processing and assessment. Eur Respir J 
1998; 11 (Suppl. 26): S20-S25. 
2. Proud D, Reynolds CJ, Lichtenstein LM, Kagey 
Sobotka A, Togias A. Intranasal salmeterol inhibits 
allergen-induced vascular permeability but not mast 
cell activation or cellular infiltration. Clin Exp Allergy 
1998; 28: 868-875. 
3. Dente FL, Bancalari L, Bacci E, et al. Effect of a single 
dose of salmeterol on the increase in airway eosinophils 
induced by allergen challenge in asthmatic subjects. 
Thorax 1999; 54: 622-624. 
4. Haahtela T, Jarvinen M, Kava T, et al. Effects of 
reducing or discontinuing inhaled budesonide in 
patients with mild asthma. N Engl J Med 1994; 331: 
700-705. 
5. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge 
P. Eosinophil and neutrophil activity in asthma in a 
one-year trial with inhaled budesonide. The impact 
of smoking. Am J Respir Crit Care Med 1996; 153: 
1519-1529. 
6. Djukanovic R, Lai CKW, Wilson JW, et al. Bronchial 
mucosal manifestations of atopy: a comparsion of 
markers of inflammation between atopic asthmatics, 
atopic nonasthmatics and healthy controls. Eur Respir 
J 1992; 5: 5388544. 
7. Jeffery PK. Differences and similarities between chronic 
obstructive pulmonary disease and asthma. Clin Exp 
Allergy 1999; 29(Suppl. 2): 14-26. 
8. Wenzel SE, Schwartz LB, Langmack EL, et al. 
Evidence that severe asthma can be divided pathologi- 
cally into two inflammatory subtypes with distinct 
physiologic and clinical characteristics. Am J Respir 
Crit Care Med 1999; 160: 1001-1008. 
9. Spezia E, Del Co1 G, Richelli C, Sette L, Boner AL. 
Nedocromil sodium vs. sodium cromoglycate pressur- 
ized aerosol in the prevention of bronchoconstriction 
induced by ultrasonic nebulized distilled water in 
asthmatic children. Pediatr Pulmonol 1993; 16: 243-247. 
10. Pocock S. Clinical Trials: A Practical Approach. 
Chichester, New York: John Wiley and Sons, 1996. 
11. Batter P. Multiple testing in clinical trials. Stat Med 
1991; 10: 871-889. 
12. Bland MJ, Altman DG. Multiple significance tests: the 
Bonferroni method. BMJ 1995; 310: 170. 
13. Richmond I, Booth H, Ward C, Walters EH. Intra- 
subject variability in airway inflammation in biopsies in 
mild to moderate stable asthma. Am J Respir Crit Care 
Med 1996; 153: 899-903. 
14. Boulet L-P, Turcotte H, Boutet M, Dube J, Gagnon M, 
Laviolette M. Influence of salmeterol on chronic and 
allergen-induced airway inflammation in mild allergic 
asthma: a pilot study. Curr Ther Res 1997; 58: 240-259. 
15. Faul JL, Demers EA. Burke CM, Poulter LW. The 
reproducibility of repeat measures of airway inflamma- 
tion in stable atopic asthma. Am J Respir Crit Care 
Med 1999; 160: 1457-1461. 
16. Ohrui T, Funayama T, Sekizawa K, Yamaya M, Sasaki 
H. Effects of inhaled beclomethasone dipropionate on 
serum IgE levels and clinical symptoms in atopic 
asthma. Clin Exp Allergy 1999; 29: 3577361. 
17. Faul JL, Leonard CT, Burke CM, Tormey VJ, Poulter 
LW. Fluticasone propionate induced alterations to 
lung function and the immunopathology of asthma 
over time. Thorax 1998; 53: 753-761. 
18. Gannon PF, Newton DT, Pantin CF, Burge PS. Effect 
of the number of peak expiratory flow readings per day 
on the estimation of diurnal variation. Thorax 1998; 53: 
790-792. 
19. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin 
RJ. Alveolar tissue inflammation in asthma. Am J 
Respir Crit Care Med 1996; 154: 150551510. 
58 L. W. POULTER ETAL 
20. Dehaut P, Rachiele A, Martin RR, Malo JL. Hista- 
mine dose-response curves in asthma: reproducibility 
and sensitivity of different indices to assess response. 
Thorax 1983; 38: 516-522. 
21. Djukanovic R, Dahl R, Jarjour NN, Aalbers R. Safety 
of biopsies and bronchoalveolar lavage. Eur Respir J 
1998; 11 (Suppl. 26): S39-S41. 
